
10x Genomics rose 250.3% from $15.70 to $54.99, ahead of the S&P 500's +11.2%. Its worst day was Oct 6 (−17.5%), and its low came Dec 12 at $15.46.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
10x Genomics closed at its lowest level of the year, 1.5% below where the year started.
−6.5% · S&P 500 −1.1%
EPS of $-0.13 missed the $-0.10 estimate on $166.0M revenue (est. $159.1M); FY revenue guidance of $600.0M–$625.0M against the $624.2M consensus.
Story events cover the past 12 months · Times ET
+3.5% · S&P 500 +0.1%
10x Genomics shares rose 12.6%, while the S&P 500 fell 0.6%.
+12.6% · S&P 500 −0.6%
EPS of $-0.10 beat the $-0.10 estimate on $150.8M revenue (est. $146.4M); FY revenue guidance of $600.0M–$625.0M against the $612.5M consensus.
−3.7% · S&P 500 +0.8%
10x Genomics shares rose 15.0%, while the S&P 500 rose 0.8%.
+15.0%, the year's best day · S&P 500 +0.8%
EPS of $-0.14 missed the $-0.06 estimate on $151.0M revenue (est. $146.7M); FY revenue guidance of $610.0M–$630.0M against the $613.8M consensus.
+14.1% · S&P 500 +0.6%
10x Genomics closed at its highest level of the year, 522.5% above where the year started.
+4.5% · S&P 500 +0.7%
EPS of $-0.15 missed the $-0.07 estimate on $150.7M revenue (est. $147.7M); FY revenue guidance of $625.0M–$635.0M against the $620.4M consensus.
+2.1% · S&P 500 +0.3%
Where it ended: a close of $54.99 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 11, 2027 (EPS est. $-0.07, revenue est. $178.1M).
Nothing in the past 12 months.
All TXG dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for TXG and SPY from Benzinga historical bars. Not investment advice.